

03/04/02  
JCS1 U.S. PTO

03-06-02  
U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

JCS12 U.S. PTO  
10/09/1300  
03/04/02

**UTILITY PATENT APPLICATION  
TRANSMITTAL LETTER  
UNDER 37 C.F.R. 1.53(b)**

ATTORNEY DOCKET NO.:  
11245/46211

Address to:  
Assistant Commissioner for Patents  
Washington D.C. 20231  
Box Patent Application

Transmitted herewith for filing is the patent application of

Inventor(s): **Patricia ROCKWELL and Neil I. GOLDSTEIN**

For: **COMBINATION METHODS OF INHIBITING TUMOR GROWTH  
WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR  
RECEPTOR ANTAGONIST**

Enclosed are:

1. 84 sheets of specification, 6 sheets of claims, and 1 sheet of abstract;
2. 27 sheets of drawings
3. Declaration (Unsigned)
4. Appointment of Power of Attorney by Assignee of Entire Interest (Unsigned)
5. Continuing application information:

This application is a Continuation-in-Part of U.S. Patent Application Serial No. 09/798,689, filed **March 2, 2001**, which is a Continuation-in-Part of U.S. Patent Application Serial No. 09/401,163, filed **September 22, 1999**, which is a Continuation of U.S. Patent Application Serial No. 08/967,113, filed **November 10, 1997**, which is a Continuation of U.S. Patent Application Serial No. 08/779,450, filed **January 7, 1997**, which is a Continuation-in-part of U.S. Patent Application Serial No. 08/706,804, filed **September 3, 1996**, which is a Continuation-in-part of U.S. Patent Application Serial No. 08/476,533, filed **June 7, 1995**, which is a Continuation of U.S. Patent Application Serial No. 08/326,552, filed **October 20, 1994**, which is a Continuation-in-part of U.S. Patent Application Serial No. 08/196,041, filed **February 10, 1994**

6. Other enclosures:
  1. 33 Pages of Sequence Listing; one (1) diskette and Sequence Listing Statement

7. The filing fee has been calculated as shown:

	NUMBER FILED	NUMBER EXTRA*	RATE (\$)	FEE (\$)
BASIC FEE				740.00
TOTAL CLAIMS	67 - 20 =	47	18.00	846.00
INDEPENDENT CLAIMS	4 - 3 =	1	84.00	84.00
MULTIPLE DEPENDENT CLAIM PRESENT			280.00	
*Number extra must be zero or larger			TOTAL	1,670.00
If applicant is a small entity under 37 C.F.R. §§ 1.9 and 1.27, then divide total fee by 2, and enter amount here.			SMALL ENTITY TOTAL	835.00

8. Please charge the required application filing fee of \$835.00 to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**.
9. The Commissioner is hereby authorized to charge payment of the following fees, associated with this communication or arising during the pendency of this application, or to credit any overpayment to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**:
- A. Any additional filing fees required under 37 C.F.R. § 1.16;
  - B. Any additional patent application processing fees under 37 C.F.R. § 1.17;
  - C. Any additional patent issue fees under 37 C.F.R. § 1.18;
  - D. Any additional document supply fees under 37 C.F.R. § 1.19;
  - E. Any additional post-patent processing fees under 37 C.F.R. § 1.20; or
  - F. Any additional miscellaneous fees under 37 C.F.R. § 1.21.
10. A duplicate copy of this sheet is enclosed.

Dated: March 4, 2002

By:

  
Kathryn M. Lumb (Reg. No. 46,885)

KENYON & KENYON  
One Broadway  
New York, New York 10004  
(212) 425-7200 (phone)  
(212) 425-5288 (facsimile)

**PATENT**  
**Docket No. 11245/46211**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor : ROCKWELL, et al.  
Serial No. : To Be Assigned  
Filing Date : Herewith  
For: COMBINATION METHODS OF INHIBITING  
TUMOR GROWTH WITH A VASCULAR  
ENDOTHELIAL GROWTH FACTOR RECEPTOR  
ANTAGONIST  
Examiner : To Be Assigned  
Art Unit : To Be Assigned

Assistant Commissioner for Patents  
Washington D.C. 20231  
BOX SEQUENCE

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope addressed  
to: Assistant Commissioner for Patents, Washington, D.C. 20231 on  
March 4, 2002

Kathryn M. Lumb (Reg. No. 46,885)

**SUBMISSION OF**  
**SEQUENCE LISTING STATEMENT**

SIR:

**STATEMENT UNDER 37 CFR §1.821(f)**

I hereby state that the information recorded in computer readable form is identical to  
the written sequence listing.

Respectfully submitted,  
KENYON & KENYON

Dated: March 4, 2002

By:

  
Kathryn M. Lumb  
Reg. No. 46,885

One Broadway  
New York, NY 10004  
Direct Dial: 212-908-6204  
Fax: 212-425-5288